Retraining the Immune System: How Imcyse's Approach to T1D Works
Researchers are exploring a novel strategy to treat Type 1 diabetes by retraining the immune system to stop attacking beta cells rather than replacing them. Imcyse, a Belgian biotech company, is developing immunotherapies designed to restore immune tolerance.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Type 1 diabetes occurs when the immune system mistakenly attacks insulin-producing beta cells in the pancreas
- Rather than replacing damaged beta cells, Imcyse's approach focuses on retraining the immune system to recognize beta cells as safe
- The company was founded as a spin-off of the Catholic University of Leuven in Belgium about 10 years ago
- This immunotherapy strategy represents a different way of thinking about treating autoimmune diseases like Type 1 diabetes
Understanding the T1D Problem
Type 1 diabetes is fundamentally an autoimmune disease. In this condition, the body's own immune system becomes the attacker, mistakenly targeting insulin-producing beta cells in the pancreas. This misdirected immune response damages or destroys these critical cells, leading to insufficient insulin production and high blood sugar.
A New Direction: Immune Retraining
Rather than focusing on replacing lost beta cells, Imcyse is exploring a different solution: retraining the immune system itself. The goal is to help the immune system become accustomed to beta cells again, essentially reorganizing it to stop the attack and restore tolerance to the body's own insulin-producing cells.
About Imcyse's Work
Imcyse was founded approximately 10 years ago as a spin-off from the Catholic University of Leuven in Belgium. The company later relocated and is now based in Belgium, where it continues to develop immunotherapies aimed at treating autoimmune diseases including Type 1 diabetes. The company's approach uses a strategy called epitope engineering to help the immune system learn to tolerate beta cells.
Evidence label
Origin: YouTube / WebsEdgeMedicine (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Cure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Cure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Cure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Cure & AdvancementsPig Islet Cells and Encapsulation: A New Path Forward for Type 1 Diabetes TreatmentVideo report, corroborated with 5 indexed studies
- Cure & AdvancementsBeta Cell Replacement and Regeneration: How Scientists Are Rethinking Type 1 Diabetes TreatmentVideo report, corroborated with 3 indexed studies
- Cure & AdvancementsFDA-Approved Teplizumab: What We Know About Delaying Type 1 DiabetesVideo report, corroborated with 3 indexed studies